Prodrome Sciences and Kyoto Prefectural University of Medicine (Department of Epidemiology for Community Health and Medicine) are proud to announce they have begun a collaborative biomarker research study to investigate longitudinal biomarker changes associated with dietary lifestyle diseases, dementia, cancer, and locomotive syndrome using Prodrome Sciences’ patented comprehensive metabolomics technology and blood samples collected as part of the Japan Multi-Institutional Collaborative Cohort Study (J-MICC) from this year.
Prodrome Sciences will perform comprehensive metabolomics analyses on over 5,000 blood samples collected from 2012 through 2019. Prodrome Sciences and Kyoto will work together to investigate the relationship between biochemical changes associated with aging, dietary lifestyles, and disease. Epidemiologically, the large representative population combined with the longitudinal collection of both clinical data and biological samples will enable Prodrome Sciences and Kyoto scientists to investigate biochemical changes that occur prior to disease. The goals of the research collaboration are to better understand the biochemical changes that precede and ultimately cause disease and how dietary and lifestyle activities either increase or decrease a person’s risk of getting disease. Ultimately, this information can be used to develop effective diagnostic, therapeutic, and lifestyle strategies to prevent disease and promote healthy aging.
Dr. Dayan Goodenowe, Founder, President, and CEO of Prodrome Sciences, is an expert on the biochemical basis of disease with over 19 patents in the areas of diagnostic biomarkers, diagnostic technology, and therapeutics. “We are excited to work with the Kyoto prefectural university scientists to investigate predictive biomarkers of lifestyle diseases, dementia, and locomotive syndrome. The importance of well designed and executed longitudinal studies of this kind cannot be over-stated. The data generated from advanced technologies such as Prodrome Sciences’ comprehensive metabolomics technology is only as good as the quality of the biospecimens. We are pleased to be able to contribute our technology to such an important human health project.”
Prodrome Sciences is an integrated molecular diagnostics and therapeutics company founded in 2016 by Dr. Dayan Goodenowe and is the exclusive licensee of Dr. Goodenowe’s patented complex analysis technology. Prodrome Sciences uses the technology to advance next-generation products and services with the goal of reducing the number of people that develop and die from disease and to promote optimal health.
Kyoto Prefectural University of Medicine is one of the oldest medical universities in Japan with a history of 140 years, starting with Kyoto Medical School Hospital in 1872 (Meiji 5). As a university established for the hospital, the center trains doctors and nurses rooted in the clinic within the region with the largest network of related hospitals in Japan.